Related Experiment Video

Updated: Aug 10, 2025

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein
07:08

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein

Published on: January 16, 2020

5.8K

Analysis of KRAS-Ligand Interaction Modes and Flexibilities Reveals the Binding Characteristics

Zheng Zhao1,2, Niraja Bohidar1, Philip E Bourne1,2

  • 1School of Data Science, University of Virginia, Charlottesville, Virginia 22904, United States.

Journal of Chemical Information and Modeling
|February 13, 2023
PubMed

Insights

Researchers explored KRAS binding pockets and drug interactions to aid in developing new KRAS-targeted cancer therapies. This structural systems pharmacology approach identifies key features for rational drug design.

Area of Science:

  • Oncogene research
  • Structural systems pharmacology
  • Drug discovery and development

Background:

  • KRAS is a significant oncogene and a crucial target for cancer therapy.
  • Despite decades of research, only one KRAS-targeted drug, Sotorasib, is currently approved.
  • The need for novel KRAS inhibitors drives further investigation into its structural and binding characteristics.

Purpose of the Study:

  • To characterize the binding pockets of KRAS.
  • To determine the ligand-binding features of KRAS complexes.
  • To provide insights for rational drug design targeting KRAS.

Main Methods:

  • Employed a structural systems pharmacology approach.
  • Characterized three distinct KRAS binding sites: nucleotide-binding, Switch-I/II, and Switch-II/α3 pockets.
  • Utilized molecular dynamics (MD) simulations to assess binding site flexibility and ligand accommodation.

Main Results:

  • Identified and characterized three distinct KRAS binding pockets.
  • Determined ligand-binding features using encoded KRAS-inhibitor interaction fingerprints.
  • Demonstrated the flexibility of these binding sites to accommodate various ligands.

Conclusions:

  • The study provides a detailed understanding of KRAS binding site features and ligand interactions.
  • Findings facilitate the rational design of novel KRAS-targeted drugs.
  • This research supports the ongoing development of effective cancer therapies.

More Related Videos

Determination of Protein-ligand Interactions Using Differential Scanning Fluorimetry13:26

Determination of Protein-ligand Interactions Using Differential Scanning Fluorimetry

Published on: September 13, 2014

61.8K
Application of Biolayer Interferometry BLI for Studying Protein-Protein Interactions in Transcription07:18

Application of Biolayer Interferometry BLI for Studying Protein-Protein Interactions in Transcription

Published on: July 26, 2019

13.8K

Related Concept Videos

Ligand Binding Sites02:40

Ligand Binding Sites

Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
13.0K
Ligand Binding and Linkage00:49

Ligand Binding and Linkage

Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked.  In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.8K
The Equilibrium Binding Constant and Binding Strength02:18

The Equilibrium Binding Constant and Binding Strength

The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
13.1K
Conserved Binding Sites01:49

Conserved Binding Sites

Many proteins’ biological role depends on their interactions with their ligands, small molecules that bind to specific locations on the protein known as ligand-binding sites. Ligand-binding sites are often conserved among homologous proteins as these sites are critical for protein function.
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
4.3K
The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
2.0K
Protein-protein Interfaces02:04

Protein-protein Interfaces

Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
12.6K